NTLA · Intellia Therapeutics, Inc.
$11.74
-1.59% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-4.5
Dividend yield
—
Beta
1.82
Avg volume
5M
Employees
0K
Daily Change %
-1.59%
5 Days Change
-6.36%
10 Days Change
-5.95%
30 Days Change
-1.32%
60 Days Change
-8.37%
Month to Day Change
-5.95%
Year to Day Change
32.70%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NTLA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
Goldman Sachs
Sell$9.00
-24.6% vs priceMorgan Stanley
Equal-Weight$15.00
+25.7% vs priceRBC Capital
Sector Perform$15.00
+25.7% vs priceWells Fargo
Equal-Weight$15.00
+25.7% vs priceBarclays
Overweight$14.00
+17.4% vs priceJP Morgan
Underweight$5.00
-58.1% vs priceBank of America
Buy$30.00
+151.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | Citizens | Reiterates | Market Outperform | $30.00 |
| 2026-09-09 | Wedbush | Maintains | Neutral | $12.00 → $13.00 |
| 2026-09-09 | HC Wainwright & Co. | Reiterates | Buy | $25.00 |
| 2026-08-25 | Citizens | Reiterates | Market Outperform | $30.00 |
| 2026-08-07 | Evercore ISI Group | Upgrade | In-Line → Outperform | $16.00 → $24.00 |
| 2026-07-16 | Wolfe Research | Downgrade | Peer Perform → Underperform | $0.00 → $9.00 |
| 2026-07-10 | Wedbush | Maintains | Neutral | $12.00 → $17.00 |
| 2026-06-16 | Canaccord Genuity | Maintains | Buy | $49.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.4% below the 50-day MA ($12.54).
- Price vs 200-day MA: Trading 7.0% below the 200-day MA ($12.63).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.10) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($8.04) and high ($27.98).
NTLA Price Chart
Loading chart for NTLA…
Fundamentals
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 13.5% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$80B 3.2% YTD
ARGX
argenx SE
$62B 17.0% YTD
MRNA
Moderna, Inc.
$57B 363.3% YTD
RVMD
Revolution Medicines, Inc.
$44B 155.3% YTD
ONC
BeOne Medicines Ltd.
$39B 12.5% YTD
RPRX
Royalty Pharma plc
$34B 54.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -37.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.